## **Press Release**



# Santen's CO<sub>2</sub> emission reduction targets endorsed by the Science Based Targets (SBT) initiative

July 8, 2021, Osaka, Japan - Santen Pharmaceutical Co., Ltd. (Head office in Osaka; hereinafter "Santen") has won endorsement from the Science Based Targets (SBT) initiative that Santen's mid- to long-term CO<sub>2</sub> emission reduction targets are science-based to achieve the Paris Climate Agreement's goal to "limit the global temperature increase to well below 2, preferably to 1.5 degrees Celsius above preindustrial levels."

Santen has ESG materiality tasks (priority management tasks) defined with the aim of contributing to our society's sustainable development and enhancing Santen's mid- to long-term corporate values. One of them is 'conservation of the global environment.' Based on the recognition that it is one of the top priority issues for the entire human race, Santen has adopted the 'Santen Vision for the Earth 2050' (environmental vision for 2050) and a set of environmental targets for 2030 to achieve the vision, thereby fulfilling social responsibility and consolidating the business foundation for sustainable growth. As part of this effort, Santen has won SBT endorsement for its CO<sub>2</sub> emission reduction targets.

- Santen's mid- to long-term CO<sub>2</sub> emission reduction targets
  - Scope1 2<sup>\*\*1</sup>: Reducing CO<sub>2</sub> emissions by 50% by 2030 from the 2019 level (equivalent to the 1.5 degrees Celsius goal for 2050 under the Paris Agreement\*<sup>2</sup>)
  - Scope3 Category 1<sup>\*\*1</sup>(unconsolidated): Reducing CO<sub>2</sub> emissions by 15% by 2030 from the 2019 level (equivalent to the 2 degrees Celsius goal for 2050 under the Paris Agreement)
  - %1 Scope1 : Direct greenhouse gas emissions from sources owned or controlled by a company (fuel combustion and industrial processes)
    - $Scope 2: Indirect \ greenhouse \ gas \ emissions \ from \ the \ generation \ of \ purchased \ energy, \ such \ as \ electricity, \ heat, \ and \ steam$
    - Scope3: Category 1: Indirect greenhouse gas emissions, other than Scope 1 and 2 emissions, resulting from a company's value chain activities, which are not owned or controlled by the company. Among them, Category 1 emissions are emissions from all purchased goods and services.
  - Paris Agreement: An agreement that sets the goal of holding the increase in the global temperature to well below 2, preferably to
    15 degrees Celsius above preindustrial levels

Santen will continue to contribute to the sustainable development of our society with a focus on:

- Measures against Climate Change: aiming to achieve carbon neutrality in all countries and regions where the company operates, through technological innovations to enable the conversion, extensive reusing and highly efficient use of energy sources at its factories / facilities.
- Environmental Load Reduction: application of technological innovations for comprehensive use of sustainable resources and materials in all products for Establishment of a Recycling-based Society.

#### SBT initiative

The Science Based Targets initiative is a collaboration between CDP, the United Nations Global Compact (UNGC), World Resources Institute (WRI) and the World Wide Fund for Nature (WWF)." It encourages private enterprises to adopt science-based targets for reducing greenhouse gas emissions in order to achieve the international long-term goal of limiting global temperature rise to well-below 2 degrees Celsius above pre-industrial levels.

#### <Reference>

Science Based Targets https://sciencebasedtargets.org/

### **About Santen**

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries.

Toward realizing "WORLD VISION" (Happiness with Vision), the world Santen ultimately aspires to achieve, as a "Social Innovator", we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.

With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen's website (<a href="www.santen.com">www.santen.com</a>).

#### Contact

Corporate Communications Group Santen Pharmaceutical Co., Ltd.

E-mail: communication@santen.com